Tarsus Pharmaceuticals, Inc. TARS
Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS) is an ophthalmology drug developer. Its lead program, XDEMVY (lotilaner ophthalmic solution) 0.25%, is in Phase 2 for Demodex blepharitis. Its next catalyst on record is TP-04: KORE Phase 2 topline results (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: TP-04 — KORE Phase 2 topline results (H1 2027). 8 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| XDEMVY (TP-03) | Demodex blepharitis (marketed in US; MGD data from Ersa/Rhea trials) | small molecule | Approved |
| TP-04 (lotilaner gel), KORE | Ocular rosacea | small molecule | Phase 2 |
| TP-05 (oral lotilaner), Calliope | Lyme disease prophylaxis (and community malaria reduction) | small molecule | Phase 2 |
| IRX-101 (acquired with iRenix, July 2026) | Ocular antiseptic for intravitreal injection (Phase 2b/3 RELIEF completed; Phase 3 COMFORT planned) | small molecule | Phase 2 |
Recent results and decisions
- Nov 3, 2026completed enrollment Tarsus completed enrollment in the Phase 2 Calliope trial of TP-05 for the prevention of Lyme disease.
Completed enrollment in the Phase 2 Calliope trial for the potential prevention of Lyme disease.
Filing - Aug 6, 2026completed enrollment Completed enrollment in the Calliope Phase 2 trial of TP-05.
Completed enrollment for Calliope, a Phase 2 trial evaluating TP-05, a novel investigational lotilaner-based oral prophylactic designed to kill ticks carrying Lyme disease before potential disease transmission.
Filing - Jul 8, 2026met RELIEF Phase 2b/3 (n=154) met both co-primary endpoints vs povidone-iodine: ~50% relative reduction in post-procedural pain and ~25% reduction in corneal staining (both p=0.0003).
In the completed Phase 2b/3 RELIEF trial involving 154 patients, IRX-101 demonstrated statistically significant improvements on two co-primary endpoints versus povidone-iodine
Filing
2 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 ophthalmology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.